R. Ramlau Et Al. , "Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial," JOURNAL OF CLINICAL ONCOLOGY , vol.30, no.29, pp.3640-3647, 2012
Ramlau, R. Et Al. 2012. Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial. JOURNAL OF CLINICAL ONCOLOGY , vol.30, no.29 , 3640-3647.
Ramlau, R., Gorbunova, V., Ciuleanu, T. E., Novello, S., Ozguroglu, M., GÖKSEL, T., ... Baldotto, C.(2012). Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial. JOURNAL OF CLINICAL ONCOLOGY , vol.30, no.29, 3640-3647.
Ramlau, Rodryg Et Al. "Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial," JOURNAL OF CLINICAL ONCOLOGY , vol.30, no.29, 3640-3647, 2012
Ramlau, Rodryg Et Al. "Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial." JOURNAL OF CLINICAL ONCOLOGY , vol.30, no.29, pp.3640-3647, 2012
Ramlau, R. Et Al. (2012) . "Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial." JOURNAL OF CLINICAL ONCOLOGY , vol.30, no.29, pp.3640-3647.
@article{article, author={Rodryg Ramlau Et Al. }, title={Aflibercept and Docetaxel Versus Docetaxel Alone After Platinum Failure in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: A Randomized, Controlled Phase III Trial}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2012, pages={3640-3647} }